http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 15:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+CADIAN+CAPITAL+MANAGEMENT%2C+LP/26929582.html si-local-file:///var/storage/secattach/20260814/26929582.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+CADIAN+CAPITAL+MANAGEMENT%2C+LP/26929582.html Fri, 14 Aug 2026 15:35:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+CADIAN+CAPITAL+MANAGEMENT%2C+LP/26929582.html si-local-file:///var/storage/secattach/20260814/26929582.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+CADIAN+CAPITAL+MANAGEMENT%2C+LP/26929582.html Fri, 14 Aug 2026 15:35:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26922606.html si-local-file:///var/storage/secattach/20260813/26922606.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26922606.html Thu, 13 Aug 2026 17:06:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26922606.html si-local-file:///var/storage/secattach/20260813/26922606.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26922606.html Thu, 13 Aug 2026 17:06:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+11++Filed+by%3A+SHELTON+JERRELL/26907450.html si-local-file:///var/storage/secattach/20260811/26907450.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+11++Filed+by%3A+SHELTON+JERRELL/26907450.html Tue, 11 Aug 2026 18:49:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+11++Filed+by%3A+SHELTON+JERRELL/26907450.html si-local-file:///var/storage/secattach/20260811/26907450.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+11++Filed+by%3A+SHELTON+JERRELL/26907450.html Tue, 11 Aug 2026 18:49:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+SHELTON+JERRELL/26906371.html si-local-file:///var/storage/secattach/20260811/26906371.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+SHELTON+JERRELL/26906371.html Tue, 11 Aug 2026 16:31:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+SHELTON+JERRELL/26906371.html si-local-file:///var/storage/secattach/20260811/26906371.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+SHELTON+JERRELL/26906371.html Tue, 11 Aug 2026 16:31:00 -0400 CYRX O.01522978 http://www.streetinsider.com/Earnings/Cryoport+%28CYRX%29+Misses+Q2+EPS+by+1c/26885783.html <p>Cryoport (NASDAQ: CYRX) reported Q2 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $48.97 million versus the consensus estimate of $48.21 million.</p><p>For earnings history and earnings-related data on Cryoport (CYRX) <a href="http://www.streetinsider.com/ec_earnings.php?q=CYRX">click here</a>.</p> http://www.streetinsider.com/Earnings/Cryoport+%28CYRX%29+Misses+Q2+EPS+by+1c/26885783.html Thu, 06 Aug 2026 17:50:18 -0400 CYRX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cryoport%2C+Inc.++++++++++++For%3A+Jun+30/26885373.html si-local-file:///var/storage/secattach/20260806/26885373.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cryoport%2C+Inc.++++++++++++For%3A+Jun+30/26885373.html Thu, 06 Aug 2026 17:03:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cryoport%2C+Inc.++++++++++++For%3A+Jun+30/26885373.html si-local-file:///var/storage/secattach/20260806/26885373.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cryoport%2C+Inc.++++++++++++For%3A+Jun+30/26885373.html Thu, 06 Aug 2026 17:03:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+06/26884737.html si-local-file:///var/storage/secattach/20260806/26884737.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+06/26884737.html Thu, 06 Aug 2026 16:32:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+06/26884737.html si-local-file:///var/storage/secattach/20260806/26884737.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+06/26884737.html Thu, 06 Aug 2026 16:32:00 -0400 CYRX O.01522978 http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/Press+Releases/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter revenue grew 8% year-over-year to <money>$49.0 million</money></i></li><li><i>Life Sciences Services revenue increased 15% year-over-year</i></li><li><i>BioStorage/BioServices revenue grew 25% year-over-year </i></li><li><i>Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of <chron>June 30, 2026</chron></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4747596-1&amp;h=3799568095&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.</p> <div http://www.streetinsider.com/PRNewswire/Cryoport+Reports+Second+Quarter+2026+Financial+Results/26883538.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 A.50216946 CYRX O.01522978 O.20026344 O.57762027